Database : MEDLINE
Search on : acromegaly [Words]
References found : 9353 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 936 go to page                         

  1 / 9353 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29523357
[Au] Autor:Streuli J; Harris AG; Cottiny C; Allagnat F; Daly AF; Grouzmann E; Abid K
[Ad] Address:Service of Clinical Pharmacology, Catecholamine and Peptides Laboratory, Centre Hospitalier Universitaire Vaudois (CHUV), 1001 Lausanne, Switzerland.
[Ti] Title:Cellular effects of AP102, a somatostatin analog with balanced affinities for the hSSTR2 and hSSTR5 receptors.
[So] Source:Neuropeptides;, 2018 Mar 02.
[Is] ISSN:1532-2785
[Cp] Country of publication:Netherlands
[La] Language:eng
[Ab] Abstract:BACKGROUND: Somatostatin analogs (SSAs) are first-line medical therapy for the treatment of acromegaly and neuroendocrine tumors that express somatostatin receptors (SSTR). Somatostatin suppresses secretion of a large number of hormones through the stimulation of the five SSTR. However, unbalanced inhibition of secretion as observed with the highly potent SSAs pasireotide causes hyperglycaemia mainly by inhibiting insulin secretion. In contrast, AP102 a new SSAs has neutral effect on blood glucose while suppressing GH secretion. Our objective was to establish the cellular effects of AP102 on SSTR2 and SSTR5 that may explain the differences observed between AP102 and other SSAs. METHODS: We compared the binding and agonist activity of AP102 with somatostatin-14, octreotide and pasireotide in HEK293 cells transfected with human SSTR2 and SSTR5 receptors. SSAs signal transduction effects (cAMP concentrations) were measured in forskolin-treated cells in the presence of SSAs. Proliferation and apoptotic effects were determined and binding assays were performed using I- somatostatin-14. RESULTS: AP102 has comparable affinity and agonist effect to octreotide at SSTR2 (IC50's of 112 pM and 244 pM, respectively; EC50's of 230 pM and 210 pM, respectively) in contrast to pasireotide that exhibits a 12-27 fold higher IC50 (3110 pM) and about 5-fold higher EC50 (1097 pM). At SSTR5, AP102 has much higher affinity and stimulating effect than octreotide (IC50's of 773 pM and 16,737 pM, respectively; EC50's of 8526 pM and 26,800 pM), and an intermediate affinity and agonist effect between octreotide and pasireotide. AP102, octreotide and pasireotide have variable anti-proliferative effects on HEK cells transfected with SSTR2 and SSTR5. CONCLUSION: AP102 is a new SSA that better reduces signaling at SSTR2 than SSTR5 and prevents cell proliferation at both receptors. The euglycaemic effect of AP102 observed in preclinical studies may be related to this intermediate agonistic potency between pasireotide and octreotide at SSTR2 and SSTR5.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180310
[Lr] Last revision date:180310
[St] Status:Publisher

  2 / 9353 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29520805
[Au] Autor:Kasuki L; Dalmolin MD; Armondi Wildemberg LE; Gadelha MR
[Ad] Address:Neuroendocrinology Research Center / Endocrinology Division - Medical School and Hospital Universitário Clementino Fraga Filho - Universidade Federal do, Rio de Janeiro, Rio de Janeiro, Brazil.
[Ti] Title:Treatment escape reduces the effectiveness of cabergoline during long-term treatment of acromegaly in monotherapy or in association with first-generation somatostatin receptor ligands.
[So] Source:Clin Endocrinol (Oxf);, 2018 Mar 09.
[Is] ISSN:1365-2265
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:BACKGROUND: Few studies evaluated the use of cabergoline (CAB) for acromegaly treatment in monotherapy or in combination with first-generation somatostatin receptor ligands (SRLs). AIM: Evaluate the efficacy, predictors of response and safety of CAB treatment in acromegaly both in monotherapy and in combination with SRLs. METHODS: We retrospectively collected demographic, biochemical, tumor and treatment data. Short-term disease control was defined as random GH level <1.0 µg/L and normal age-matched IGF-I level after 3-6 months of treatment with the higher dose used. Long-term disease control was defined as maintenance of normal GH and IGF-I levels at the last visit (at least nine months of treatment). RESULTS: 82 patients were studied. The median total time of treatment in monotherapy or in combination with SRLs was 14 months (3 - 124) and 34 months (3 - 88), respectively. Short-term disease control was observed in six (21%) patients in the monotherapy group and in 20 (32%) in the combination group. Treatment escape was observed in one patient after 16 months of CAB monotherapy and in six (30%) patients with combination therapy (after a median of 38 months), resulting in long-term disease control of 18% and 23%, respectively. Hyperprolactinemia was a predictor of response to monotherapy and pre-treatment GH level to combination treatment. CONCLUSION: We presented the results of the largest single-center study with CAB in monotherapy and in combination with SRL. The efficacy of CAB in acromegaly seems to be lower than that of other drugs, and treatment escape may occur after a long-term follow-up. This article is protected by copyright. All rights reserved.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:Publisher
[do] DOI:10.1111/cen.13595

  3 / 9353 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29520625
[Au] Autor:Kreitschmann-Andermahr I; Kohlmann J; Kleist B; Hirschfelder U; Buslei R; Buchfelder M; Siegel S
[Ad] Address:Department of Neurosurgery, University of Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany. ilonka.kreitschmann@uk-essen.de.
[Ti] Title:Oro-dental pathologies in acromegaly.
[So] Source:Endocrine;, 2018 Mar 08.
[Is] ISSN:1559-0100
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:PURPOSE: Oro-dental pathologies (ODP) such as enlargement of the tongue, mandibular prognathism, and spaced teeth are characteristic features of acromegaly. Their frequency of occurrence during the course of the disease is largely unresolved. Purpose of this study was to assess ODP and oro-dental treatments in patients with acromegaly with regard to the length of the diagnostic process, tumor histology, and quality of life (QoL). METHODS: Single-center retrospective survey study using questionnaires on dental symptoms, diagnostic process, and treatment in patients with acromegaly operated on a growth hormone-secreting pituitary adenoma. The association between ODP and QoL was assessed using the Short-Form 36 (SF-36) Health Survey. RESULTS: 145/314 patients completed the questionnaires. 80.7% were affected by any ODP, most frequently enlargement of the tongue (57.9%), spaced teeth (42.8%), mandibular growth (24.1%), and mandibular prognathism (22.1%). ODP were significantly more frequent in patients with sparsely vs. densely granulated adenomas (p = 0.045). Early diagnosis within 2 years was associated with significantly fewer ODP than later diagnosis (68.5 vs. 87.2%, p = 0.009). Treatments included dental crowns (16.6%), dental bridges (12.4%), dental implants (9.7%), dental prostheses (3.4%), orthodontal (i.e., braces, 6.9%), and surgical correction of the teeth (2.1%). Physical QoL was significantly lower in patients with ODP than in those without (p = 0.014). CONCLUSION: In our large series of patients, four of five patients were affected by ODP at any time during the course of the disease. The results highlight the importance of early identification and treatment of oro-dental problems in patients with acromegaly as hallmarks of the disease.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:Publisher
[do] DOI:10.1007/s12020-018-1571-y

  4 / 9353 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29272449
[Au] Autor:Park SH; Ku CR; Moon JH; Kim EH; Kim SH; Lee EJ
[Ad] Address:Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
[Ti] Title:Age- and Sex-Specific Differences as Predictors of Surgical Remission Among Patients With Acromegaly.
[So] Source:J Clin Endocrinol Metab;103(3):909-916, 2018 Mar 01.
[Is] ISSN:1945-7197
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Context: Sex and age are factors conferring resistance to medical treatment in patients with acromegaly. However, their impact on outcomes of transsphenoidal-selective adenomectomy (TSA) has not been evaluated. Objective: To analyze age- and sex-related differences concerning surgical outcomes of growth hormone (GH)-secreting pituitary adenomas. Design: Retrospective. Setting: Single-center tertiary hospital. Participants: Patients with acromegaly (n = 463) who underwent TSA between January 2000 and July 2014. Intervention: TSA. Main Outcome Measurements: Tumor characteristics and surgical outcomes. Results: Sex differences existed in the baseline insulinlike growth factor-1 levels and the mean tumor size. Overall, surgical remission rates were 89.7% and 76.5% in male and female patients, respectively (P < 0.001). Total tumor tissue resection was performed in 92.6% and 85.8% of male and female participants, respectively (P = 0.021). Premenopausal women had a higher proportion of pituitary adenoma with cavernous sinus invasion than did men aged <50 years (35.3% vs 21.7%, P = 0.007). In immediate postoperative, 75-g oral glucose tolerance tests, fewer premenopausal women reached <1 ng/dL nadir GH levels than did men aged <50 years (59.9% vs 87.7%, P < 0.001). Surgical results were similar in both sexes among older patients (≥50 years). However, premenopausal women had significantly lower long-term remission rates than did men aged <50 years (69.3% vs 88.0%, P < 0.001). Conclusion: Premenopausal women with acromegaly tend to have larger tumors, more aggressive tumor types, and lower remission rates than do men. However, further studies on the clinical implications are needed.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1712
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:In-Data-Review
[do] DOI:10.1210/jc.2017-01844

  5 / 9353 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
SciELO Brazil full text

[PMID]: 29267504
[Au] Autor:Mendes GA; Haag T; Trott G; Rech CGSL; Ferreira NP; Oliveira MC; Kohek MB; Pereira-Lima JFS
[Ad] Address:Programa de Pós-Graduação em Patologia, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, RS, Brasil.
[Ti] Title:Expression of E-cadherin, Slug and NCAM and its relationship to tumor invasiveness in patients with acromegaly.
[So] Source:Braz J Med Biol Res;51(2):e6808, 2017 Dec 11.
[Is] ISSN:1414-431X
[Cp] Country of publication:Brazil
[La] Language:eng
[Ab] Abstract:Pituitary adenomas account for 10-15% of primary intracranial tumors. Growth hormone (GH)-secreting adenomas account for 13% of all pituitary adenomas and cause acromegaly. These tumors can be aggressive, invade surrounding structures and are highly recurrent. The objective of this study was to evaluate E-cadherin, Slug and neural cell adhesion molecule (NCAM) expression in GH-secreting pituitary adenomas and its relationship to tumor invasiveness. A cross-sectional study of patients who underwent hypophysectomy due to GH-secreting pituitary adenoma from April 2007 to December 2014 was carried out. The medical records were reviewed to collect clinical data. Immediately after surgery, tumor samples were frozen in liquid nitrogen and stored in a biofreezer at -80°C for assessment of E-cadherin 1 (CDH1), SLUG (SNAI2), and NCAM (NCAM1) by real-time PCR. The samples were fixed in formalin and embedded in paraffin for immunohistochemical analysis of E-cadherin and NCAM. Thirty-five patients with acromegaly were included in the study. Of these, 65.7% had invasive tumors. Immunohistochemically, E-cadherin was expressed in 96.7% of patients, and NCAM in 80% of patients. There was no statistically significant relationship between tumor grade or invasiveness and immunohistochemical expression of these markers. Regarding gene expression, 50% of cases expressed CDH1, none expressed SNAI2, and 53.3% expressed NCAM1. There was no statistically significant relationship between tumor grade or invasiveness and gene expression of CDH1, SNAI2, and NCAM1. The absence of Slug overexpression and of E-cadherin and NCAM suppression suggests that expression of these markers is not associated with tumor invasiveness in GH-secreting pituitary adenomas.
[Mh] MeSH terms primary: Acromegaly/pathology
Adenoma/pathology
Cadherins/analysis
Neural Cell Adhesion Molecules/analysis
Pituitary Neoplasms/pathology
Snail Family Transcription Factors/analysis
[Mh] MeSH terms secundary: Acromegaly/genetics
Acromegaly/metabolism
Adenoma/chemistry
Adenoma/genetics
Adolescent
Adult
Aged
Biomarkers, Tumor/analysis
CD56 Antigen/analysis
Cross-Sectional Studies
Female
Gene Expression
Humans
Immunohistochemistry
Male
Middle Aged
Neoplasm Grading
Neoplasm Invasiveness
Pituitary Neoplasms/chemistry
Pituitary Neoplasms/genetics
Real-Time Polymerase Chain Reaction
Statistics, Nonparametric
Young Adult
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Biomarkers, Tumor); 0 (CD56 Antigen); 0 (Cadherins); 0 (NCAM1 protein, human); 0 (Neural Cell Adhesion Molecules); 0 (SNAI1 protein, human); 0 (Snail Family Transcription Factors)
[Em] Entry month:1803
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[Js] Journal subset:IM
[Da] Date of entry for processing:171222
[St] Status:MEDLINE

  6 / 9353 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29516525
[Au] Autor:Burulday V; Dogan A; Sahan MH; Arikan S; Güngünes A
[Ad] Address:Department of Radiology, Kirikkale University, Kirikkale, Turkey.
[Ti] Title:Ultrasound Elastography of the Median Nerve in Patients With Acromegaly: A Case-Control Study.
[So] Source:J Ultrasound Med;, 2018 Mar 08.
[Is] ISSN:1550-9613
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:OBJECTIVES: The aim of this study was to compare the cross-sectional area and ultrasound elastographic findings of the median nerve of patients with acromegaly and healthy participants. METHODS: The acromegaly group comprised 15 patients with a previous diagnosis of acromegaly, and an age- and sex-matched control group included healthy participants. Strain elastographic and shear wave elastographic findings and the cross-sectional areas of the groups were compared. A 6-15-MHz multifrequency transducer was used for ultrasound evaluations. RESULTS: A total of 30 hands of 15 patients with acromegaly (7 male and 8 female) with a mean age ± SD of 50.00 ± 10.17 years and 40 hands of 20 healthy control participants (9 male and 11 female) with a mean age of 49.50 ± 10.17 years were taken into consideration for statistical analyses. The cross-sectional area of the patients with acromegaly was significantly higher than that of the healthy controls (13.43 ± 3.12 versus 8.32 ± 1.94 mm ; P < .05). Median nerve stiffness was significantly increased in the acromegaly group compared with the control group (axial and longitudinal, 37.15 ± 6.4 and 37.0 ± 6.19 versus 18.7 ± 4.1 and 19.2 ± 3.58 kPa, respectively; P < .001). CONCLUSIONS: These preliminary results have demonstrated that patients with acromegaly seem to have increased stiffness and cross-sectional area of the median nerve compared with healthy participants.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:Publisher
[do] DOI:10.1002/jum.14591

  7 / 9353 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29514715
[Au] Autor:Atiase Y; Yorke E; Akpalu J; Opoku-Asare B; Adjei P; Amissah-Arthur MB; Akpalu A
[Ad] Address:Department of Medicine and Therapeutics, School of Medicine and Dentistry, College of Health Sciences, University of Ghana, Legon, Accra, Ghana. yacobat@gmail.com.
[Ti] Title:Pachydermoperiostosis in a patient with chronic hepatitis B virus infection referred as acromegaly: a case report.
[So] Source:J Med Case Rep;12(1):59, 2018 Mar 08.
[Is] ISSN:1752-1947
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:BACKGROUND: Primary hypertrophic osteoarthropathy also known as pachydermoperiostosis is a rare genetic disorder that has often been confused with acromegaly because of similar clinical features. Vascular endothelial growth factors which have been implicated in the clinical features of pachydermoperiostosis, have also been shown to be present in chronic hepatitis and implicated in the malignant transformation of hepatitis B infection to hepatocellular carcinoma. To the best of our knowledge there is one reported case of pachydermoperiostosis with chronic hepatitis B infection. We do not imply a causal relationship between pachydermoperiostosis and hepatitis B infection because pachydermoperiostosis is a genetic disorder; however, the question is raised whether hypertrophic osteoarthropathy is one of the many extrahepatic manifestations of chronic hepatitis B infection. CASE PRESENTATION: A 21-year-old African (Ghanaian) man with chronic hepatitis B infection was referred to our Endocrine unit as having acromegaly with changing facial features, enlarging hands and feet, and large knee joint effusions which affected activities of daily living. He was finally diagnosed as having pachydermoperiostosis when acromegaly, rheumatological disorders, as well as cardiopulmonary disorders were ruled out. He improved with arthrocentesis, a tapering regime of steroids, non-steroidal anti-inflammatory drugs, and proton pump inhibitors. CONCLUSIONS: The possible role of hepatitis B in hypertrophic osteoarthropathy, that is, secondary hypertrophic osteoarthropathy, needs to be explored; however, with digital clubbing in his father our patient is likely to have pachydermoperiostosis.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:In-Process
[do] DOI:10.1186/s13256-018-1578-2

  8 / 9353 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29395968
[Au] Autor:Guevara-Aguirre J; Guevara A; Palacios I; Pérez M; Prócel P; Terán E
[Ad] Address:Colegio de Ciencias de la Salud, Universidad San Francisco de Quito, Ecuador; Instituto de Endocrinología IEMYR, Quito, Ecuador. Electronic address: jguevara@usfq.edu.ec.
[Ti] Title:GH and GHR signaling in human disease.
[So] Source:Growth Horm IGF Res;38:34-38, 2018 02.
[Is] ISSN:1532-2238
[Cp] Country of publication:Scotland
[La] Language:eng
[Ab] Abstract:Along with its inherent properties in growth promotion, cell division and regeneration, growth hormone (GH) exerts a variety of miscellaneous and widespread actions on the human body after binding to its receptor (GHR). Indeed, GH influences the metabolism of carbohydrates, lipids and proteins; shapes body composition, influences cardiovascular profile, quality of life, and induces other direct and indirect physiologic effects. Besides this salutary actions, GH and its derived peptide insulin-like growth factor-I (IGF-I), main product of the GH/GHR interaction, have been implicated in the genesis of diseases such as cancer and insulin-resistant diabetes. The effects of these peptides are difficult to discern in healthy individuals but can be better evaluated in disease states in which their action in target tissues is abnormal. In consequence, we selected acromegaly and Laron syndrome due to GH receptor deficiency (GHRD) as models for excess and absence of GH action, and focused in the role of GH/GHR signaling in the genesis of cancer and diabetes. Considering that malignancy has been linked at epidemiological level to type 2 diabetes and high body mass index, suggesting that hyperinsulinemia is an independent contributor to cancer genesis and progression, we propose that the GH-derived IGF-I is also an independent influence for progression to neoplasia since its absence associates with less DNA damage, diminished mutagenesis and efficient apoptosis. Regarding development of type 2 diabetes, we support the notion that GH, by influencing insulin sensitivity via its counter-regulatory properties on carbohydrate metabolism, is an important contributor for development of this disease.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180307
[Lr] Last revision date:180307
[St] Status:In-Process

  9 / 9353 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29505842
[Au] Autor:Milanese L; Martini C; Scaroni C; Dassie F; Ceccato F; Puppa AD; Denaro L; Bommarito G; Citton V; Ermani M; Maffei P; Manara R
[Ad] Address:Neurosurgery, Department of Neuroscience, University of Padua, via Giustiniani 1, 35138 Padova, Italy. Electronic address: laura_ny10@yahoo.com.
[Ti] Title:Radiotherapy in acromegaly: long-term brain parenchymal and vascular magnetic resonance changes.
[So] Source:J Neuroradiol;, 2018 Mar 02.
[Is] ISSN:0150-9861
[Cp] Country of publication:France
[La] Language:eng
[Ab] Abstract:BACKGROUND: Radiation therapy (RT) effectiveness on hormonal reduction is proven in acromegaly; however, collateral long-term effects are still undetermined. This transversal neuroimaging study on a large cohort of acromegalic patients aimed to investigate the rate of parenchymal and vascular changes after RT. MATERIALS AND METHODS: Thirty-six acromegalic patients underwent RT (RT+) after unsuccessful surgery and were compared to RT- acromegalic patients matched for age, gender, adenoma features, clinical and surgical history. All patients underwent magnetic resonance angiography (MRA) to investigate intracranial artery abnormalities and FLAIR sequence to assess white matter changes according to the Wahlund scale. RESULTS: RT+ acromegalic patients had a higher rate of controlled disease (29/36 vs 12/36, p<0.001). RT+ acromegalic patients had MRI/MRA evaluation 15.3±9.6 years after RT. RT+ acromegalic patients had a significantly higher Wahlund score than RT- acromegalic patients (6.03±6.41 vs 2.53±3.66, p=0.006) due to increased white matter signal abnormalities at the level of the temporal lobes, the basal ganglia (insula) and the infra-tentorial regions, bilaterally. Among RT+ patients one died because of temporo-polar anaplastic astrocytoma, one suffered from a stroke due to right internal carotid artery occlusion, one presented with cystic degeneration of the temporal poles. Long-dated RT (>10 years before MR evaluation) was associated with a higher rate of RT-related white matter changes (p=0.0004). CONCLUSIONS: RT seems to have created a cohort of patients with brain parenchymal changes whose clinical and cognitive impact is still unknown. These patients might require a prolonged MRI and MRA follow-up to promptly detect delayed RT-related complications and minimize their clinical consequences.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180305
[Lr] Last revision date:180305
[St] Status:Publisher

  10 / 9353 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 29501516
[Au] Autor:Roca E; Mattogno PP; Porcelli T; Poliani L; Belotti F; Schreiber A; Maffezzoni F; Fontanella MM; Doglietto F
[Ad] Address:Neurosurgery, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia - Brescia, Italy.
[Ti] Title:Plurihormonal ACTH-GH pituitary adenoma: case report and systematic literature review.
[So] Source:World Neurosurg;, 2018 Feb 28.
[Is] ISSN:1878-8769
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:INTRODUCTION: Plurihormonal adenomas (PHA) represent 10-15% of all functioning pituitary adenomas. The most frequent hormonal association is represented by prolactin and growth hormone (GH). AIM: To describe a rare case of functional ACTH and GH microadenoma, together with a systematic literature review on PHA. METHODS: PubMed was searched using the terms "plurihormonal pituitary adenoma", "ACTH, GH pituitary adenoma", and "Acromegaly AND Cushing's disease". CASE REPORT: A 60-year-old woman was incidentally diagnosed with a pituitary microadenoma. Endocrine assessment documented increased levels of IGF-1 and GH; ACTH and cortisol values were within normal range. Echocardiography documented ventricular hypertrophy. Due to clinical and biochemical evidence of acromegaly, surgery was recommended. Postoperatively, hormonal replacement was started because of adrenal insufficiency. Her anti-hypertensive therapy was discontinued due to evidence of normal blood pressure values. Histological examination revealed an ACTH-GH PHA with two distinct populations of secreting cells. At 3-year follow-up, the patient showed stable clinical remission and was no longer on replacement therapy. LITERATURE REVIEW: In the 17 articles that were selected for literature review, only 20% (4/20) of patients presented with clinical signs of both diseases. Histologically, 19 were pituitary adenomas composed of two distinct cell populations, while only in 1 case was there evidence of a single cell producing both ACTH and GH. CONCLUSIONS: This is an additional case to the 20 previously described ACTH-GH PHA. Awareness of this relatively rare entity is clinically relevant. ACTH-GH PHA cytogenesis is still a matter of debate and several hypotheses have been postulated.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180304
[Lr] Last revision date:180304
[St] Status:Publisher


page 1 of 936 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information